{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:56:27Z","timestamp":1781254587143,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K10584"],"award-info":[{"award-number":["JP22K10584"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.012","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:36:19Z","timestamp":1774035379000},"page":"e774-e779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns and Outcomes of Patients With Acute Myeloid Leukemia in Japan in the Pre-venetoclax Era"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-3757","authenticated-orcid":false,"given":"Shuhei","family":"Kida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-3287","authenticated-orcid":false,"given":"Toshitaka","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-8637","authenticated-orcid":false,"given":"Kayo","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-4971","authenticated-orcid":false,"given":"Isao","family":"Miyashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.clml.2026.03.012_bib0001","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.03.012_bib0002","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/cncr.32697","article-title":"Assessing the efficacy-effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics","volume":"126","author":"Phillips","year":"2020","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.clml.2026.03.012_bib0003","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2026.03.012_bib0004","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of population-based observational studies with randomized trials in oncology","volume":"37","author":"Soni","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.03.012_bib0005","first-page":"124","article-title":"Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study","volume":"10","author":"Brandwein","year":"2020","journal-title":"Am J Blood Res"},{"issue":"17","key":"10.1016\/j.clml.2026.03.012_bib0006","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1182\/bloodadvances.2024013102","article-title":"Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020","volume":"8","author":"Liu","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2026.03.012_bib0007","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-020-04051-0","article-title":"Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century","volume":"99","author":"Yanada","year":"2020","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.clml.2026.03.012_bib0008","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00277-021-04631-8","article-title":"Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry","volume":"100","author":"Fuji","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.clml.2026.03.012_bib0009","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00277-020-04342-6","article-title":"Analysis of real-world data in patients with relapsed\/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era","volume":"100","author":"Fuji","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.012_bib0010","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12185-021-03150-6","article-title":"Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry","volume":"114","author":"Kida","year":"2021","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.012_bib0011","doi-asserted-by":"crossref","first-page":"7134","DOI":"10.1038\/s41598-022-11225-5","article-title":"Between-hospital variations in 3-year survival among patients with newly diagnosed gastric, colorectal, and lung cancer","volume":"12","author":"Morishima","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clml.2026.03.012_bib0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12885-022-10411-y","article-title":"Patterns of staging, treatment, and mortality in gastric, colorectal, and lung cancer among older adults with and without preexisting dementia: a Japanese Multicentre Cohort Study","volume":"23","author":"Morishima","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.03.012_bib0013","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12876-023-02898-x","article-title":"An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese Cancer Registry Cohort Study","volume":"23","author":"Hirao","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"10.1016\/j.clml.2026.03.012_bib0014","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.03.012_bib0015","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2026.03.012_bib0016","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/10428194.2021.2002321","article-title":"Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy","volume":"63","author":"Miyamoto","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2026.03.012_bib0017","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12185-022-03334-8","article-title":"Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy","volume":"116","author":"Yoshida","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.03.012_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2019.01.008","article-title":"A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent","volume":"78","author":"Bell","year":"2019","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2026.03.012_bib0019","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cncr.33873","article-title":"Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: a population-based analysis in the modern era","volume":"128","author":"Kennedy","year":"2022","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.clml.2026.03.012_bib0020","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.03.012_bib0021","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.03.012_bib0022","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.03.012_bib0023","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy: a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.clml.2026.03.012_bib0024","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.03.012_bib0025","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.clml.2026.03.012_bib0026","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1002\/cncr.26033","article-title":"Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia","volume":"117","author":"Juliusson","year":"2011","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.clml.2026.03.012_bib0027","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.03.012_bib0028","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:06:16Z","timestamp":1781251576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000777"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Outcomes of Patients With Acute Myeloid Leukemia in Japan in the Pre-venetoclax Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}